Abstract Metabolic inhibitors were used in an attempt to determine the manner by which mycobacterial ribonucleic acid (myc. RNA) immunizes against tuberculosis. Inhibitors of protein synthesis (streptomycin sulfate, chloramphenicol, cycloheximide) and inhibitors of DNA-dependent RNA polymerase (rifampin) had no effect on the immune response of mice vaccinated with myc. RNA. All of these compounds except streptomycin sulfate, however, inhibited antibody formation under the same conditions. In contrast, inhibitors of deoxyribonucleic acid (DNA) synthesis significantly reduced the immune response. Five-fluoro-deoxyuridine (FUDR), which inhibits thymidine synthetase, when injected just before vaccination, reduced the immune response but had no effect if injected 18 hr after vaccination. These results indicated that early synthesis of DNA was important, and that DNA once formed was not affected by FUDR. Ethidium bromide, proflavine and chloroquine were each mixed with myc. RNA and injected into mice. Under these circumstances the immune response was significantly lowered. In addition, chloroquine was injected at various times and significant reduction in the immune response occurred only if it were injected 1 hr or later after vaccination. This compound binds with DNA, and shows again the necessity for the presence of DNA in the immune process. Actinomycin D injected at the time of vaccination or 1 hr after vaccination had no effect on the immune response. However, if actinomycin D was injected 18 hr after vaccination or injected daily for 4 days after vaccination, a marked reduction in the immune response occurred. These results indicated that actinomycin D, which inhibits RNA transcription may have inhibited the replication of myc. RNA. A mutogenic agent, hydroxylamine, also reduced significantly the immunogenic activity of myc. RNA. These results closely paralleled those obtained by other investigators in studies aimed at eliciting the mode of replication of oncogenic viruses. The replication of these RNA tumor viruses is unique in that DNA synthesis is required for viral RNA replication early after infection, and there is a requirement for RNA transcription. The similarity between the manner by which myc. RNA immunizes and RNA tumor viruses replicate is discussed, and a comparison also is made of the two diseases, tuberculosis and tumors formed by oncogenic viruses. These results strongly suggest that myc. RNA may immunize against tuberculosis by forming a DNA template in the host cell which then transcribes specific information for the replication of myc. RNA, and thereby transforms a normal cell into a specific immune cell. If correct, this would provide a new concept of the nature of cellular immunity of tuberculous infection.